| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
CD47 (integrin-associated protein), a cell surface protein that binds to signal regulatory protein alpha (SIRPalpha) on macrophages, delivering a "don't eat me" signal that inhibits phagocytosis. CC-90002 binds to CD47 on tumor cells, blocking CD47-SIRPalpha interaction and enabling Fc receptor-mediated phagocytosis.
|
|---|---|
| ln Vitro |
CC-90002 exhibits a subnanomolar dissociation constant (Kd) value, indicating its strong affinity for binding to CD47[1]. The CD47-SIRPa interaction can be blocked by CC-90002, with an IC50 value in the subnanomolar range[1]. In concentration-dependent manner, CC-90002 exhibits inhibitory effects on ALL and AML cell lines [1].
In vitro, CC-90002 binds to CD47 with a subnanomolar Kd value, indicating its strong affinity. The CD47-SIRPalpha interaction can be blocked by CC-90002, with an IC50 value in the subnanomolar range, in a concentration-dependent manner. It promotes the phagocytosis of tumor cells by macrophages. |
| ln Vivo |
In tumor xenograft models, CC-90002 exhibits strong dose-dependent anticancer efficacy and tumor regression[1].
No published in vivo data. As an anti-CD47 antibody, CC-90002 would be expected to inhibit tumor growth in mouse xenograft models by promoting macrophage-mediated phagocytosis. In combination with other therapies (e.g., rituximab or azacitidine), it may enhance anti-tumor efficacy. |
| Enzyme Assay |
A direct binding ELISA or surface plasmon resonance (SPR) is used to determine Kd. Recombinant human CD47 is immobilized on a sensor chip, and serially diluted CC-90002 is flowed over. The Kd is calculated from the association/dissociation rates. Alternatively, the IC50 for blocking CD47-SIRPalpha binding is measured by a competition ELISA.
|
| Cell Assay |
For in vitro phagocytosis assays, human monocyte-derived macrophages are co-cultured with fluorescently labeled tumor cells (e.g., AML or lymphoma cells) at a 1:1 to 1:5 ratio in the presence of CC-90002 (0.01-100 ug/mL) for 2-4 hours. The percentage of double-positive cells (macrophage marker+ and tumor cell dye+) is quantified by flow cytometry.
|
| Animal Protocol |
No published in vivo data. For research use, a xenograft mouse model is used: NSG mice are engrafted with human CD34+ hematopoietic stem cells (HIS mice) or subcutaneously implanted with AML/l lymphoma cells. CC-90002 is administered intravenously at 1-20 mg/kg twice weekly. Tumor growth is monitored, and tumor tissues are harvested for IHC (CD47, TUNEL) and flow cytometry analysis of immune cell infiltration.
|
| ADME/Pharmacokinetics |
CC-90002 is a humanized anti-CD47 monoclonal antibody with a molecular weight of 150 kDa. Detailed PK parameters are not publicly available. As an IgG antibody, it is expected to have a long half-life (14-21 days in humans) and is administered intravenously. Clearance is low, and volume of distribution is consistent with the vascular space.
|
| Toxicity/Toxicokinetics |
Toxicological data are not publicly available. As an anti-CD47 antibody that blocks the "don't eat me" signal, potential toxicities may include anemia, thrombocytopenia, and other hematologic side effects due to CD47 expression on red blood cells and platelets. However, CC-90002 is humanized and may have reduced RBC binding compared to other anti-CD47 antibodies.
|
| References | |
| Additional Infomation |
CC-90002 was in clinical development for the treatment of hematologic malignancies and solid tumors but development was discontinued. It is not approved for therapeutic use. It is available for research purposes to study the role of CD47 in cancer immunotherapy and to explore combination strategies for enhancing anti-tumor immunity.
|
| Molecular Weight |
0
|
|---|---|
| CAS # |
2085844-54-6
|
| Appearance |
Colorless to light yellow liquid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
